Biovista President Dr. Aris Persidis will be presenting at the New York Biotechnology Association 2013 Annual meeting. Dr Persidis will be presenting at the “Patient Perspectives: Seeking Cures, Not Just Returns” session and discuss Biovista’s work to date with Patient Advocacy Groups. According to the organizers “patient groups and disease foundations, no longer content to … Read More
News
GEN: Seasoned Drugs Offer Therapeutic Gold Mine
Article by Caitlin Smith GEN: Genetic Engineering & Biotechnology, May 15, 2013 … Biovista has already repositioned two drugs for the progressive form of multiple sclerosis (MS), which has had few treatment options. Most MS drugs, for treatment of the relapsing-remitting form of MS, compromise the patients’ immune systems and have significant side effects. Biovista … Read More
VA BIOTECH – Concept to Commercialization
Biovista announces that its President, Dr. Aris Persidis, will participate in the “VA BIOTECH – Concept to Commercialization” Facebook event. About VA BIOTECH – Concept to Commercialization event: Charlottesville is home to some of the most cutting edge biotechnology firms in the Country. This panel, presented in partnership with U.Va. Innovation and Charlottesville Business Innovation … Read More
Biovista and DART Therapeutics Enter into Drug Repositioning Collaboration Targeting Duchenne Muscular Dystrophy
CHARLOTTESVILLE, Virginia and CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ — DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leader in systematic drug repositioning, announced today that they have entered into a research collaboration to identify and develop novel drug repositioning candidates for DMD … Read More
Biovista – NIH/DAIDS Seminar on use of MoA to predict Safety Signals
Biovista announces that its President, Dr. Aris Persidis, will give a seminar at the NIH/DAIDS Medical Officer’s Safety Forum on Thursday, March 28th. The seminar, is entitled “Using Mechanism of Action to Predict Safety Signals and Understanding Sub-Populations.” With the web being increasingly used to determine side effects of drugs, and with self-reporting patient social networking databases … Read More